Table II.
Background characteristics of recipients who underwent LDLT for HCC according to post-LDLT with or without HCC recurrence.
| Factor | All recipients (22 cases) | Recipients without post-LDLT HCC recurrence (13 cases) | Recipients with post-LDLT HCC recurrence (9 cases) |
|---|---|---|---|
| Age, years (mean ± SD) | 56±4 (range 47–64) | 56±4 | 55±3 |
| MELD score (mean ± SD) | 14±8 (range 1–30) | 15±9 | 11±7 |
| GV/SLV (mean ± SD) | 46.3±7.0(range 36–60) | 46.1±7.5 | 46.6±7.2 |
| Donor age (mean ± SD) | 36±12 (range 20–61) | 38±13 | 35±12 |
| AFP (ng/ml) (mean ± SD) | 148±264 | 169±323 | 118±182 |
| DCP (mAU/l) (mean ± SD) | 183±388 | 85±179 | 323±573 |
| Gender (female/male) | 5/17 | 5/8 | 0/9 |
| HCV/HBV | 12/10 | 7/6 | 5/4 |
| LDLT graft (Left/Right) | 5/17 | 2/11 | 3/6 |
| Post LDLT complication, n (%) | |||
| Bile duct stenosis | 6 (27) | 4 (31) | 2 (22) |
| CMV infection | 9 (41) | 6 (46) | 3 (33) |
| ACR | 5 (23) | 2 (15) | 3 (33) |
| Immunosuppressant | |||
| CNI (FK/CyA) | 17/5 | 10/3 | 7/2 |
| Prednisolone, n (%) | 11 (50) | 8 (62) | 3 (33) |
| MMF, n (%) | 13 (59) | 8 (62) | 5 (56) |
| Child Pugh, n (%) | |||
| A | 4 (18) | 1 (8) | 3 (33) |
| B | 12 (55) | 8 (61) | 12 (55) |
| C | 6 (27) | 4 (31) | 6 (27) |
| UNOS TNM, n (%) | |||
| I,II | 6 (28) | 6 (46) | 0 |
| IV | 16 (72) | 7 (54) | 9 (100)a |
| UICC TNM, n (%) | |||
| I | 2 (9) | 2 (15) | 0 |
| II | 18 (82) | 10 (77) | 8 (89) |
| III | 2 (9) | 1 (8) | 1 (11) |
| Histological grade (poorly and combined), n (%) | 6 (27.2) | 4 (31) | 2 (22) |
| Microvascular invasion, n (%) | 16 (73) | 9 (69) | 7 (78) |
| Bile duct invasion, n (%) | 1 (5) | 1 (8) | 0 |
| Intrahepatic metastasis, n (%) | 11 (50) | 5 (39) | 6 (67) |
| SVR, n (%) | 14 (64) | 7 (54) | 7 (78) |
| Pre LDLT treatment for HCC, n (%) | 15 (68) | 9 (69) | 6 (67) |
a
P<0.05 in the comparison of the with and without post-LDLT HCC recurrence groups using χ2 test (analysis was considered statistically significant).
LDLT, living donor liver transplantation; HCC, hepatocellular carcinoma; GV/SLV, actual graft volume/recipient standard liver volume ratio; AFP, α-fetoprotein; DCP, des-γ-carboxyprothrombin; CMV, cytomegalovirus; ACR, acute cellular rejection; CNI, calcineurin inhibitor; HCV, hepatitis C viral hepatitis; HBV, hepatitis B viral hepatitis; MMF, mycophenolate mofetil; SVR, sustained viral responder for hepatitis C or B virus; SD, standard deviation.